Regenxbio (RGNX) Current Leases (2019 - 2026)
Regenxbio (RGNX) posted quarterly Current Leases of $8.3 million for Q4 2025, up 4.86% year-over-year from $7.9 million in Q4 2024, and down 8.67% quarter-over-quarter from $9.1 million in Q3 2025.
Regenxbio (RGNX) Current Leases (2019 - 2026) Analysis & Trends
Regenxbio's Current Leases history runs 7 years deep, the most recent figure standing at $8.3 million for Q4 2025.
- In Q4 2025, Current Leases rose 4.86% year-over-year to $8.3 million; the TTM figure through Dec 2025 stood at $8.3 million (up 4.86% YoY), while the FY2025 annual figure was $8.3 million, up 4.86% from the prior year.
- Current Leases for Q4 2025 stood at $8.3 million, down from $9.1 million in the prior quarter.
- The five-year high for Current Leases was $9.1 million in Q3 2025, with the low at $1.3 million in Q3 2021.
- The 5-year median for Current Leases is $6.5 million (2023), against an average of $5.5 million.
- The sharpest annual moves came in 2021 and 2022: Current Leases tumbled 62.71% in 2021, then jumped 242.29% in 2022.
- Regenxbio's Current Leases stood at $1.8 million in 2021, then surged by 242.29% to $6.0 million in 2022, then advanced by 17.86% to $7.1 million in 2023, then grew by 11.8% to $7.9 million in 2024, then climbed by 4.86% to $8.3 million in 2025.
- Business Quant data shows RGNX's Current Leases at $8.3 million in Q4 2025, $9.1 million in Q3 2025, and $8.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Regenxbio | 583.35 Mn | 477.83 Mn | 106.98 Mn | 7.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.36 Mn |
| Dec 31, 2025 | 8.29 Mn |
| Sep 30, 2025 | 9.07 Mn |
| Jun 30, 2025 | 8.05 Mn |
| Mar 31, 2025 | 7.94 Mn |
| Dec 31, 2024 | 7.90 Mn |
| Sep 30, 2024 | 7.72 Mn |
| Jun 30, 2024 | 7.30 Mn |
| Mar 31, 2024 | 7.07 Mn |
| Dec 31, 2023 | 7.07 Mn |
| Sep 30, 2023 | 6.64 Mn |
| Jun 30, 2023 | 6.33 Mn |
| Mar 31, 2023 | 6.30 Mn |
| Dec 31, 2022 | 6.00 Mn |
| Sep 30, 2022 | 3.61 Mn |
| Jun 30, 2022 | 2.83 Mn |
| Mar 31, 2022 | 2.12 Mn |
| Dec 31, 2021 | 1.75 Mn |
| Sep 30, 2021 | 1.33 Mn |
| Jun 30, 2021 | 1.71 Mn |